Literature DB >> 12870431

siRNA-mediated antitumorigenesis for drug target validation and therapeutics.

Patrick Y Lu1, Frank Y Xie, Martin C Woodle.   

Abstract

Application of siRNA to knockdown a specific gene requires target mRNA accessibility, effective intracellular delivery of siRNA into target cells and potent siRNA inhibition of target mRNA. Use of siRNA as a tool is advancing in almost every field of biomedical research, but some of the most dynamic and exciting applications of siRNA are in cancer research. This review summarizes the results obtained with siRNA in cancer, in particular functional validation of tumorigenic genes in cell culture and animal tumor models, effective siRNA delivery systems, efficiency of siRNA agents compared with antisense oligonucleotides and efforts for potential therapeutic development. Along with the rapidly growing literature on using siRNA as a functional genomic tool, there is emerging evidence that siRNA may represent a novel therapeutic modality for cancer treatment when optimized local and systemic delivery systems are available.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12870431

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  14 in total

1.  A differential proteome in tumors suppressed by an adenovirus-based skin patch vaccine encoding human carcinoembryonic antigen.

Authors:  Chun-Ming Huang; Zhongkai Shi; Tivanka S DeSilva; Masato Yamamoto; Kent R Van Kampen; Craig A Elmets; De-chu C Tang
Journal:  Proteomics       Date:  2005-03       Impact factor: 3.984

Review 2.  Cell-penetrating peptides: achievements and challenges in application for cancer treatment.

Authors:  Meong Cheol Shin; Jian Zhang; Kyoung Ah Min; Kyuri Lee; Youngro Byun; Allan E David; Huining He; Victor C Yang
Journal:  J Biomed Mater Res A       Date:  2013-07-30       Impact factor: 4.396

3.  Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis.

Authors:  Bumseok Kim; Qingquan Tang; Partha S Biswas; Jun Xu; Raymond M Schiffelers; Frank Y Xie; Aslam M Ansari; Puthupparampil V Scaria; Martin C Woodle; Patrick Lu; Barry T Rouse
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

4.  Induced apoptosis in human prostate cancer cells by blocking of vascular endothelial growth factor by siRNA.

Authors:  A Deezagi; S Ansari-Majd; N Vaseli-Hagh
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405

5.  Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.

Authors:  Zong-Xia Lu; Li-Ting Liu; Xian-Rong Qi
Journal:  Int J Nanomedicine       Date:  2011-08-11

Review 6.  Modulation of angiogenesis with siRNA inhibitors for novel therapeutics.

Authors:  Patrick Y Lu; Frank Y Xie; Martin C Woodle
Journal:  Trends Mol Med       Date:  2005-03       Impact factor: 11.951

Review 7.  The fascinating world of RNA interference.

Authors:  Afsar Raza Naqvi; Md Nazrul Islam; Nirupam Roy Choudhury; Qazi Mohd Rizwanul Haq
Journal:  Int J Biol Sci       Date:  2009-01-15       Impact factor: 6.580

8.  RNAi and cancer: Implications and applications.

Authors:  Maen Abdelrahim; Stephen Safe; Cheryl Baker; Ala Abudayyeh
Journal:  J RNAi Gene Silencing       Date:  2006-02-28

9.  Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.

Authors:  Moizza Mansoor; Alirio J Melendez
Journal:  Gene Regul Syst Bio       Date:  2008-09-22

Review 10.  Delivering small interfering RNA for novel therapeutics.

Authors:  Patrick Y Lu; Martin C Woodle
Journal:  Methods Mol Biol       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.